Abstract

We aimed to investigate the difference in serum uric acid(SUA)levels between subtypes of depression and normal population, and whether SUA can be used to identify bipolar disorder depressive episode and major depressive disorder and predict the length of hospital stay. 1543 depression patients and 1515 healthy controls were obtained according to the entry and exclusion criteria from one mental health center of a tertiary hospital in southwestern China. The diagnosis and classification of depression was in accordance with ICD-10. The SUA value was derived from fasting plasma samples analysis. The level of SUA of all the participants was quantified using Roche cobas8000-c702-MSB automatic biochemical analyzer. Data were analyzed by SPSS18.0 statistical software package. Overall, the level of SUA in patients with depression was lower than that in normal control. Specifically, males' SUA levels were in the interval of [240, 323.3) and [323.3, 406.6), and women were in the [160, 233.3] levels. The SUA level of bipolar disorder depressive episode was higher compared to major depressive disorder level. Interestingly, male patients who were hospitalized for two weeks had higher SUA than those who were hospitalized for three weeks or four weeks. Our results suggest that the length of hospital stay may be associated with SUA, and when it is difficult to make a differential diagnosis of bipolar disorder depressive episode and major depressive disorder, the level of SUA may be considered. The adjustment of SUA as a method for treating depression needs to be carefully assessed.

Highlights

  • Depression has a high prevalence and is a heavy disease burden

  • The Serum uric acid (SUA) level of bipolar disorder depressive episode was higher compared to major depressive disorder level

  • Male patients who were hospitalized for two weeks had higher SUA than those who were hospitalized for three weeks or four weeks

Read more

Summary

Introduction

Depression has a high prevalence and is a heavy disease burden. Its global prevalence rate is about 4% to 5% [1], and about 10% to 20% of people have had various types of depression in their lifetime [2,3]. It is predicted that by 2020 [4]depression will rank second in the global burden of disease. Depression is thought to be the result of genetic predisposition combined with environmental interactions, and the oxidative stress may be one of its pathogenesis [5,6]. Oxidative stress can lead to decreased brain neurogenesis and increased neuronal apoptosis [7], and it can affect the activity of 5-HT neurotransmitters and the metabolic pathways of monoamine neurotransmitters [8]. Oxidative stress and lipid per oxidation are enhanced and the total antioxidant capacity is reduced [5,6], which in turn leads to various depressive symptoms in patients

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call